Sirnaomics Ltd. 2257

HKEX · Hong Kong SAR China · Health Technology

HKD 3.75-0.05 (-1.45%)

Market closed· Oct 2, 2026, 8:08 AM UTC· HKD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Sirnaomics Ltd. 2257

HKEX · Hong Kong SAR China · Health Technology

HKD 3.75-0.05 (-1.45%)

Market closed· Oct 2, 2026, 8:08 AM UTC· HKD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-42.74% · 6MFull-screen chart

Open HKD 3.75High HKD 3.75Low HKD 3.65Close HKD 3.75Volume 16.05K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: HKD 3.80
Day range: HKD 3.65 – HKD 3.75
52-week range: HKD 3.55 – HKD 15.80
Volume: 16.05K
Market cap: HKD 426.20M
Next earnings date: 2027-04-01
Avg. volume (1Y): 238.71K

Performance

1 week

+1.47%

1 month

+0.80%

3 months

-17.39%

6 months

-45.01%

Year to date

-52.50%

1 year

-74.53%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: Hong Kong SAR China
Exchange: HKEX
Shares outstanding: 112.16M
Employees: 37
ISIN: KYG2050P1028
Beta: 0.65

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceOct 08, 2025

Cutaneous Squamous Cell Carcinoma Market Forecast Report 2025-2035, with Focus on Regeneron Pharmaceuticals, Sanofi, Merck & Co., Checkpoint Therapeutics, Incyte, and Sirnaomics

The global cutaneous squamous cell carcinoma market is set for robust growth, driven by rising skin cancer incidences and treatment advancements. This market expansion is fueled by increased UV exposure, environmental factors, and an aging population, underscoring the urgent need for early detection and innovative treatments. Breakthroughs in immunotherapy and targeted treatments, such as immune checkpoint inhibitors, are transforming care strategies. Public awareness initiatives enhance early d

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.